NCT00273858

Study Evaluating the Safety of Etanercept in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis

Open Label Study To Evaluate The Safety Profile And The Quality Of Life In Patients Receiving Etanercept For The Treatment Of Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 880 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 4 open label, non-interventional, multi-center study to evaluate the safety of Enbrel (etanercept) treatment in patients receiving etanercept 25mg sc twice weekly or 50mg of etanercept once weekly. The improvement of health-related quality of life will also be evaluated.

Detailed description

Patients already prescribed to receive etanercept for the first time for treatment of Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis according to the Summary of Product Characteristics (SmPC). Patients have been recruited sequentially based on eligibility criteria up to the number limit assigned to each site.

Conditions

• Ankylosing Spondylitis
• Arthritis, Psoriatic
• Arthritis, Rheumatoid
• Spondylitis, Ankylosing

Interventions

Type	Name	Description
OTHER	There is no Intervention. The study is observational.	The study is observational and the prescription follows the SmPC of etanercept.

Timeline

• Start date: 2006-03-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2006-01-09
• Last updated: 2011-09-12
• Results posted: 2011-07-28

Locations

9 sites across 1 country: Greece